Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies
Status:
Completed
Trial end date:
2017-12-19
Target enrollment:
Participant gender:
Summary
This study will be the first to test the anti-cancer peptide Nerofe in humans. It will
evaluate the safety, pharmacokinetic behavior, and pharmacodynamic and clinical effects of
Nerofe given intravenously every other day to patients with advanced malignant disease.